Zosano Pharma Corporation (ZSAN) saw its loss narrow to $7 million, or $0.34 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $8.12 million, or $0.68 a share.
The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $6.75 million, compared with an operating loss of $7.80 million in the previous year period.
"The pivotal study results importantly validate our technology platform, and, if approved by the FDA, point to M207's positioning as an acute treatment for migraine sufferers that is differentiated from what is currently available. I look forward to working with the team at Zosano and to bringing this exciting new drug to market." commented John P. Walker, Interim chief executive officer. "On behalf of the Board of Directors, I want to thank Konstantinos Alataris for his efforts and commitment to the company over the past two years. We wish him well in his future endeavors," added Walker.
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]